Smith Graham & Co Investment Advisors’s Phibro Animal Health PAHC Stock Holding History

Smith Graham & Co Investment Advisors’s Portfolio PAHC Stock Details PAHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$5.19M	Sell	447,909 -2,674	-0.6%	-$30.2K	0.6%	75
2023 Q3	$5.75M	Sell	450,583 -4,221	-0.9%	-$59.8K	0.72%	57
2023 Q2	$6.23M	Sell	454,804 -19,736	-4%	-$283K	0.75%	54
2023 Q1	$7.27M	Sell	474,540 -1,464	-0.3%	-$22.4K	0.88%	38
2022 Q4	$6.38M	Buy	476,004 +110,194	+30%	+$1.48M	0.78%	51
2022 Q3	$4.86M	Buy	365,810 +43,191	+13%	+$746K	0.65%	68
2022 Q2	$6.17M	Sell	322,619 -3,312	-1%	-$62.7K	0.76%	53
2022 Q1	$6.5M	Sell	325,931 -2,133	-0.7%	-$43.1K	0.68%	66
2021 Q4	$6.7M	Sell	328,064 -26,799	-8%	-$572K	0.67%	63
2021 Q3	$7.64M	Sell	354,863 -30,606	-8%	-$737K	0.77%	56
2021 Q2	$11.1M	Sell	385,469 -48,798	-11%	-$1.32M	0.98%	26
2021 Q1	$10.6M	Buy	+434,267	New	+$9.81M	0.86%	36

Other funds holding PAHC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Smith Graham & Co Investment Advisors's PAHC Position: Q4 2023 in Review

Smith Graham & Co Investment Advisors reduced its Phibro Animal Health (PAHC) stake by 0.59% in Q4 2023, selling an estimated $30.2K and leaving 447,909 shares worth $5.19M. The position accounts for 0.6% of the portfolio, ranked #75.

Smith Graham & Co Investment Advisors first reported a position in PAHC in Q1 2021 and has held it in 12 quarters since. The position peaked at $11.1M in Q2 2021. 136 funds tracked by Wall St. Rank hold PAHC as of Q4 2023.

Smith Graham & Co Investment Advisors held 447,909 shares of Phibro Animal Health worth $5.19M as of Q4 2023.
Smith Graham & Co Investment Advisors sold 2,674 Phibro Animal Health shares in Q4 2023, an estimated $30.2K.
Phibro Animal Health made up 0.6% of Smith Graham & Co Investment Advisors's portfolio in Q4 2023, its #75 holding.
Smith Graham & Co Investment Advisors first reported a position in Phibro Animal Health in Q1 2021 and has held it in 12 quarters since.
Smith Graham & Co Investment Advisors's Phibro Animal Health position peaked at $11.1M in Q2 2021.
136 funds tracked by Wall St. Rank held Phibro Animal Health as of Q4 2023.

Based on Smith Graham & Co Investment Advisors's 13F filing for Q4 2023, filed 29 Jan 2024.